ESR1 and breast cancer: Although earlier work confirmed that ERα-positive breast cancer cells are more sensitive than ERα-negative breast cells to the growth-inhibitory effects of tamoxifen, moderate antiproliferative responses to tamoxifen and to ICI-164,384 are found in ERα-negative cells [73–75].